Betina T. Blak
AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Influenza Virus Research Studies, Respiratory viral infections research
Most-Cited Works
- → Generalisability of The Health Improvement Network (THIN) database:demographics, chronic disease prevalence and mortality rates(2011)641 cited
- → Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs(2018)459 cited
- → The importance of defining periods of complete mortality reporting for research using automated data from primary care(2008)309 cited
- → SGLT-2 Inhibitors and Cardiovascular Risk(2018)129 cited
- → Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study(2020)92 cited
- → A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care(2012)58 cited
- → Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin(2012)53 cited
- → Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study(2019)51 cited
- → Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up(2017)35 cited
- → Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study(2016)31 cited